[1] Situation Reports [Internet]. Situation Reports. 2020 [cited 2020May12]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200511-covid–19-sitrep–112.pdf?sfvrsn = 813f2669_2
[2] Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV–2 infected patients. EBioMedicine. 2020;55:102763.
[3] Konig MF, Powell M, Staedtke V, et al. Preventing cytokine storm syndrome in COVID–19 using α–1 adrenergic receptor antagonists [published online ahead of print, 2020 May 26]. J Clin Invest. 2020;139642..
[4] Chen X, Zhao B, Qu Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019, Clinical Infectious Diseases,, ciaa449, https://doi.org/10.1093/cid/ciaa449
[5] Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID–19 pandemic. Lancet. 2020;395:1607–1608.
[6] Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID–19 and Cardiovascular Disease. Circulation. 2020;141:1648–1655.
[7] Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID–19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50(1):211.
[8] Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109:II18–26.
[9] Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickering G. Rapid effect of 3-
hydroxy–3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003; 93:e98–103.
[10] Fang CH, Li JJ, Hui RT. Statins, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses 2005; 64:192–6.
[11] Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, Amichay D, Almog Y. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med. 2009;17:1255–1260.
[12] Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005;17:82.
[13] Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205: 13–19.
[14] W. Guan, Z. Ni, Yu Hu, W. Liang, C. Ou, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. NEJM 2020;382:1708–20.
[15] Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID–19 in the New York City Area.JAMA 2020;323(20):2052–2059.
[16] Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid–19. N Engl J Med 2020;382:2431–2440.
[17] Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019—United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020;69:382–386. DOI: http://dx.doi.org/10.15585/mmwr.mm6913e2
[18] Ng YX, Li ZB, Chua YX, et al. Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID–19 in Singapore—January 2–February 29, 2020. MMWR Morb Mortal Wkly Rep 2020;69:307–311. DOI: http://dx.doi.org/10.15585/mmwr.mm6911e1.
[19] Wang, H.,Yuan Z, Pavel MA, Hansen SB. Cholesterol and COVID19 lethality in elderly. bioRxiv preprint 2020. doi: https://www.biorxiv.org/content/10.1101/2020.05.09.086249v2
[20] Ridker PM, Rifai N, Pfeffer MA, Sacks F, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230.
[21] McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015.
[22] Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64.
[23] Zhang J, Osawa S, Takayanagi Y, et al. Statins directly suppress cytokine production in murine intraepithelial lymphocytes. Cytokine. 2013;61:540–545.
[24] Iwata A, Shirai R, Ishii H, et al. Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clin Exp Immunol. 2012;168:234–240.
[25] van der Meij E, Koning GG, Vriens PW, et al. A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One. 2013;8:e53882.
[26] Duan HY, Liu DM, Qian P, et al. Effect of atorvastatin on plasma NT-proBNP and inflammatory cytokine expression in patients with heart failure. Genet Mol Res. 2015;14(4):15739–15748.
[27] Zeiser R. Immune modulatory effects of statins. Immunology 2018;154:69–75.
[28] Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73:1176–1180.
[29] Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis. 2001;33:1352–1357.
[30] Ma Y, Wen X, Peng J, Lu Y, Guo Z, Lu J. Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality. PLoS One. 2012;7:e51548.
[31] Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6:82.